Phase l, randomised, three-arm, parallel-group, PK study comparing SC BenepaliTM (50 mg) with EU-and US-sourced rETN (50 mg) in healthy male volunteers
ADL concentrations were determined using ELISA. PK endpoints were: AUCinf, AUClast and Cmax. Safety and immunogenicity
Abbreviations: rADL, reference adalimumab; ELISA, enzyme linked immunosorbent assay; PK, pharmacokinetics; SC, subcutaneous.
Adapted from: Lee YJ, et al. 2016.
Adapted from: Emery P, et al. 2017.
Abbreviations: oETN, originator etanercept.